

Version with Markings to Show Changes Made

Marked up versions of claims 17-19, 23, 32 and 34-35 are as follows:

17. The method of [any of claims] claim 9, [11, 13 or 15,] wherein said cell is capable of undergoing necrosis in the presence of zVAD-fmk and TNF α .

18. The method of [any of claims] claim 9, [11, 13, or 15,] wherein said cell is capable of undergoing necrosis in the presence of zVAD-fmk and DMSO.

19. The method of [any of claims] claim 9, [11, 13 or 15,] wherein said cell is mammalian.

23. The method of [any of claims] claim 9, [11, 13, or 15,] wherein said compound is in a pharmaceutically acceptable carrier.

32. The method of [any of claims] claim 24, [26, 28, or 30,] wherein said condition is a neurodegenerative disease.

34. The method of [any of claims] claim 24, [26, 28, or 30,] wherein said condition is selected from the group consisting of ischemic brain injury, ischemic heart injury, and head trauma.

35. The method of [any of claims] ~~claim~~ 24, [26, 28, or 30,] wherein said subject is a mammal.